Better Buy: Biogen vs. Bristol-Myers Squibb
You don't have to look back too far to find a time when Biogen (NASDAQ: BIIB) and Bristol-Myers Squibb (NYSE: BMY) claimed very similar market caps. That was the case in the spring of 2015. Since then, though, the two drugmakers' paths have diverged dramatically.
There are legitimate reasons why investors would want to consider buying Biogen and Bristol-Myers Squibb right now. But which of these two stocks is the better pick? Here's how Biogen and BMS stack up against each other.
Image source: Getty Images.
Source Fool.com
